The global lung cancer diagnostics market size was estimated at USD 1.63 billion in 2015. Technological advancements pertaining to tumor diagnosis contribute to market growth. The need for more efficient diagnostic systems is due to the fact that only 15% of the lung cancer cases get diagnosed while the remaining undiagnosed cancer cases develop into more aggressive forms, which reduces the 5-year survival rate to only 4% in these patients that are detected with late-stage lung cancer.
In the developing world, there has been a dramatic rise in the prevalence of smoking, which is expected to influence the incidence rate of lung malignancies in the coming years. The increasing prevalence of cancer is directly proportional to market growth as it propels the demand for early screening and diagnosis of cancer.
Global lung cancer diagnostics market, by test, 2013 - 2024, (USD Million)
The introduction of technological advancements with regard to precision, cost-effectiveness, and accuracy; the growing awareness levels amongst the population, and the availability of private & government funds for R&D to develop better tumor diagnostic tools are some of the factors anticipated to further fuel the market growth over the forecast period.
The market is segmented on the basis of type into small-cell and non-small cell lung cancer. The basis of differentiation of the tumor types is the size of the tumor cells. Small cell lung cancer (SCLC)spreads quickly in the body, which makes detection of this cancer at an early-stage difficult. However, only about 10% of the malignancies are small cell lung cancers. There are two major subtypes of SCLC, such as small-cell lung carcinoma and combined small-cell lung carcinoma.
Non-small cell lung cancer (NSCLC)is the more prominent form of cancer in terms of occurrence and accounts for 85% of lung cancer cases. Moreover, various subtypes of NSCLC include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less frequent types of NSCLCs.
In 2015, the imaging tests segment was identified as the largest test segment majorly due to the high usage rates of various imaging techniques including MRI, CT scan, and X-ray as the primary screening techniques used for cancer diagnosis. Imaging tests serve as the initial screening tool for the diagnosis of lung cancer and are useful throughout the treatment period.
The molecular tests segment is expected to witness significant growth over the forecast period with a CAGR of over10.0%. Innovations and advancements in the molecular diagnostic technology have resulted in the introduction of new diagnostic test applications and are anticipated to help this segment grow over the forecast period.
Molecular tests pertaining to lung cancer facilitate personalized treatments. These tests are used for the identification of specific proteins, genes, and other tumor-specific factors known as mutations including EGFR, BRAF, ALK, ROS1, HER2, and RET.
North America was identified as the largest regional market with revenue of over USD 520.0million in 2015. The large revenue share is attributed to the high market penetration rates of technologically advanced products, the rising patient awareness, and the rising smoking prevalence level in the region.
In addition, the presence of a favorable reimbursement framework (especially succeeding the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure are expected to boost the usage rates of diagnostics tools in North America. Initiatives, such as smoking cessation programs conducted by the American Lung Association (ALA) and campaigns to increase awareness of the symptoms of lung cancer are expected to further boost the regional market growth.
However, Asia Pacific is projected to grow at a lucrative CAGR of over 9.5% during the forecast period. Major factors responsible for the fastest growth exhibited in Asia Pacific include the rising penetration of the advanced lung cancer diagnostic tools in the region coupled with the rising awareness about the disease symptoms.
The market is consolidated in nature. Some of the global lung cancer diagnostics market players include Roche Diagnostics, bioMérieux, Qiagen N.V., Agilent Technologies, Thermo Fisher Scientific, AstraZeneca plc, Illumina Inc., Janssen Pharmaceuticals, Inc., and Sanofi S.A.
Mergers and acquisitions with an objective to cover vast distribution areas and novel product development is a key strategy that is being implemented by these market players. For instance, in August 2014, Illumina partnered with pharma majors such as Janssen Pharmaceuticals Inc., AstraZeneca plc, and Sanofi S.A. to develop gene sequencing tools for the diagnosis of lung cancer under the personalized medicine approach. Moreover, investments to ramp up research and development efforts with the aim to enhance the existent cancer diagnostic tools is expected to be a transforming decision for both, the end-users (hospitals and clinical laboratories) and the product developers.
In March 2023, Roche announced approval from the U.S. FDA for VENTANA PD-L1 (SP263) Assay. SP263 helps to identify the eligibility of non-small cell lung cancer (NSCLC) patients for treatment with Libtayo monotherapy.
In March 2023, Agilent Technologies Inc. acquired Resolution Bioscience Inc. to expand the NGS-based cancer treatment capabilities. This acquisition further strengthens Agilent's position in the cancer diagnostics market.
In January 2023, Agilent Technologies Inc. collaborated with Quest Diagnostics to enhance the accessibility of the Resolution ctDx FIRST test. The test helps to identify advanced NSCLC (non-small cell lung cancer) patients.
In March 2021, Roche announced approval from the U.S. FDA for VENTANA ALK (D5F3) CDx Assay. D5F3 helps to identify the eligibility of lung cancer patients for targeted treatment with LORBRENA (lorlatinib).
In February 2021, Sanofi announced approval from the U.S. FDA for Libtayo® (cemiplimab-rwlc). The approval aimed at first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.